TOP TEN perturbations for 1151_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1151_at
Selected probe(set): 221726_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1151_at (221726_at) across 6672 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-2.905982
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

ovarian tumor study 13 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-2.7806425
Number of Samples:18 / 12
Experimental ovarian tumor study 13
Human epithelial tumor cell samples from the ovary of patients with serous adenocarcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from healthy donors. Samples were derived by cell surface brushing.

ovarian tumor study 25 (serous ovarian cancer epithelium) / normal ovarian surface epithelium cell sample

Relative Expression (log2-ratio):-2.529561
Number of Samples:12 / 12
Experimental ovarian tumor study 25 (serous ovarian cancer epithelium)
Laser capture micro-dissected serous ovarian cancer epithelium cells derived from female individuals with primary papillary serous adenocarcinoma of the ovary.
Control normal ovarian surface epithelium cell sample
Normal ovarian surface epithelium cell (OSE) samples isolated from female individuals by laser capture micro-dissection (LCM). Indication for removal of healthy ovaries were others than ovary cancer.

C. pneumoniae study 1 / uninfected monocyte-derived dendritic cell sample

Relative Expression (log2-ratio):-2.2420464
Number of Samples:2 / 2
Experimental C. pneumoniae study 1
Monocyte-derived dendritic cells from healthy donors were infected with Chlamydia pneumoniae at a multiplicity of infection of 5 for 72 h.
Control uninfected monocyte-derived dendritic cell sample
Uninfected monocyte-derived dendritic cells from healthy donors.

dengue fever study 10 (DHF) / normal naive CD8 T cell sample

Relative Expression (log2-ratio):-2.1671724
Number of Samples:2 / 5
Experimental dengue fever study 10 (DHF)
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue hemorrhagic fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, HLA_DR+, and CD38+ effector CD8 T subtype cells were used for analysis.
Control normal naive CD8 T cell sample
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.1563673
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

Langerhans cell histiocytosis study 3 / Langerhans cell histiocytosis study 4

Relative Expression (log2-ratio):-2.1256828
Number of Samples:10 / 7
Experimental Langerhans cell histiocytosis study 3
CD3+ T-lymphocyte samples isolated from Langerhans cell histiocytosis (LCH) lesions in bone (8 cases) or skin (2 cases). Patient with different clinical status were included in this study (unifocal, single system; multifocal, single system and multifocal, multisystem disease).
Control Langerhans cell histiocytosis study 4
CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease).

pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)

Relative Expression (log2-ratio):-2.121419
Number of Samples:8 / 17
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

pediatric meningococcal sepsis study 1 (24h; blood) / normal blood sample

Relative Expression (log2-ratio):-2.0057259
Number of Samples:3 / 3
Experimental pediatric meningococcal sepsis study 1 (24h; blood)
Blood samples collected from children with (suspected) meningococcal sepsis 24 hours after admission to the pediatric intensive care unit (PICU).
Control normal blood sample
Normal blood samples collected from healthy children admitted for elective minor non-infectious surgery or MRI.

T. cruzi study 1 (HMVEC; 24h; bottom) / mock infected cardiac microvascular endothelial cell sample (24h; bottom)

Relative Expression (log2-ratio):-1.9885092
Number of Samples:2 / 2
Experimental T. cruzi study 1 (HMVEC; 24h; bottom)
Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS.
Control mock infected cardiac microvascular endothelial cell sample (24h; bottom)
Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, mock-infected and harvested 24 hours post mock infection with 2% FBS medium. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS.

Organism: Homo sapiens
Gene: 1151_at
Selected probe(set): 220960_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1151_at (220960_x_at) across 6672 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.458747
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

scleroderma study 8 (blood; anifrolumab; 1mg/kg/wk; multiple dose; 56d) / scleroderma study 8 (blood; baseline; 1mg/kg/wk; multiple dose)

Relative Expression (log2-ratio):1.79842
Number of Samples:4 / 4
Experimental scleroderma study 8 (blood; anifrolumab; 1mg/kg/wk; multiple dose; 56d)
Whole blood samples collected from adult systemic sclerosis patients at day 56 after a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1. ATC code:---
Control scleroderma study 8 (blood; baseline; 1mg/kg/wk; multiple dose)
Whole blood samples from adult systemic sclerosis patients before a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1.

interferon-alpha-kinoid study 1 (240ug; 112d) / placebo treated whole blood sample

Relative Expression (log2-ratio):-1.7904015
Number of Samples:2 / 7
Experimental interferon-alpha-kinoid study 1 (240ug; 112d)
Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 3 doses of 240ug INK-K at day 0, 7 and 58. Sample was taken 112 days after the first application of TNF-K. ATC code:---
Control placebo treated whole blood sample
Whole blood samples of patients with systemic lupus erythematosus after treatment with placebo (0.9% NaCl; hemocyanin as carrier). Patients had 3 doses at day 0, 7 and 58. Sample was taken 112 days after the first application of TNF-K.

systemic onset JIA study 6 (baseline; placebo) / normal blood sample

Relative Expression (log2-ratio):-1.7092705
Number of Samples:22 / 22
Experimental systemic onset JIA study 6 (baseline; placebo)
Whole blood samples collected from systemic juvenile idiopathic arthritis patients at baseline (day 1), prior to placebo treatment. Patients were 2 to 19 years of age with a confirmed diagnosis of febrile SJIA with high disease activity. aACR response was scored at day 15. Concomitant therapy with a prednisone equivalent (up to 1.0 mg/kg/day) and stable doses of nonsteroidal anti inflammatory drugs and methotrexate (≤20 mg/m2 per week) were permitted.
Control normal blood sample
Whole blood samples collected from healthy volunteers.

major open chest surgery study 1 (blood) / normal blood sample

Relative Expression (log2-ratio):-1.6387548
Number of Samples:11 / 20
Experimental major open chest surgery study 1 (blood)
Whole blood samples achieved post-surgically from patients who had a major open chest surgery. Patients were recruited pre-operatively and blood samples were collected within 24 hours following surgery. Patients had a high risk of clinical outcomes consistent with systemic inflammation due to physical trauma and wound healing and thus a high risk of developing SIRS (Systemic Inflammatory Response Syndrome). All study participants were 18 years or older with a body mass index < 40. Exclusion criteria involved any systemic immunological disorders including Systemic Lupus Erythromatosus, Crohn’s disease and Diabetes (type 1).Patients who were transplant recipients or were currently receiving chemotherapy treatment for cancer were also excluded.
Control normal blood sample
Whole blood samples from healthy volunteers without concurrent illnesses at the time of blood collection or any past history of immunological dysfunction. All study participants were 18 years or older with a body mass index < 40.

systemic onset JIA study 7 (tocilizumab; 3m; neutrophils) / systemic onset JIA study 7 (tocilizumab; baseline; neutrophils)

Relative Expression (log2-ratio):1.481102
Number of Samples:4 / 4
Experimental systemic onset JIA study 7 (tocilizumab; 3m; neutrophils)
Neutrophil granulocyte samples from patients with systemic onset of juvenile rheumatoid arthritis (SoJIA) collected after 3 months of tocilizumab treatment. Patients were included in the study when they showed signs of persistent inflammation refractory to methotrexate treatment. All patients responded to the tocilizumab treatment: attained ACR90 (American College of Rheumatology criteria) and normal CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) values. ATC code:
Control systemic onset JIA study 7 (tocilizumab; baseline; neutrophils)
Neutrophil granulocyte samples from patients with systemic onset of juvenile rheumatoid arthritis (SoJIA) collected before the initiation of tocilizumab treatment. Patients were included in the study when they showed signs of persistent inflammation refractory to methotrexate treatment.

attention deficit hyperactivity disorder (ADHD) study 1 / normal blood sample

Relative Expression (log2-ratio):1.4675798
Number of Samples:2 / 24
Experimental attention deficit hyperactivity disorder (ADHD) study 1
Blood samples from generally healthy children ( age > 24 month) with attention deficit hyperactivity disorder (ADHD). Patients undergone diagnostic assessment, using DSMIV-TR criteria - ADOS and ADI-R, and comprehensive clinical testing (cognitive testing, language measures, medical history, height and weight, head circumference, and behavioral questionnaires).
Control normal blood sample
Blood samples from generally healthy children, which were followed in an endocrine clinic due to idiopathic short stature and constitutional delay of growth. Only children with no abnormal findings were enrolled in the study. Children diagnosed with intellectual disability or any neurological disorder were excluded.

methylprednisolone; immunoglobulin (IVIG) study 1 / Kawasaki disease study 2 (non-responder)

Relative Expression (log2-ratio):1.4061108
Number of Samples:4 / 10
Experimental methylprednisolone; immunoglobulin (IVIG) study 1
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after combined treatment with intravenous methylprednisolone (30mg/kg/2h) followed by intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to simple IVIG therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients exhibited good response to the combined therapy. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:, ,
Control Kawasaki disease study 2 (non-responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

pediatric meningococcal sepsis study 1 (24h; blood) / normal blood sample

Relative Expression (log2-ratio):-1.3752766
Number of Samples:3 / 3
Experimental pediatric meningococcal sepsis study 1 (24h; blood)
Blood samples collected from children with (suspected) meningococcal sepsis 24 hours after admission to the pediatric intensive care unit (PICU).
Control normal blood sample
Normal blood samples collected from healthy children admitted for elective minor non-infectious surgery or MRI.

pediatric septic shock study 5 (survivor) / normal blood sample

Relative Expression (log2-ratio):-1.3566198
Number of Samples:24 / 15
Experimental pediatric septic shock study 5 (survivor)
Whole blood from children with septic shock who survived. Blood samples for RNA isolation were obtained within 24 hours of admission to the pediatric intensive care unit, referred as day 1 of septic shock. Children were < 10 years old. To determine surviva rate, patients were followed for 28 days. Severity of illness was calculated using the PRISM III score.
Control normal blood sample
Whole blood samples from normal children < 10 years of age. Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study. Characteristics of the group: 15 children; mean age (±SD) 3.1 ± 3.5 y; 8 males, 7 females; ethnicity: African-American or African 6 subjects, Asian 4 subjects, Caucasian 5 subjects.